These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 25514659)

  • 1. An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions.
    Johnson ME; Bobrovskaya L
    Neurotoxicology; 2015 Jan; 46():101-16. PubMed ID: 25514659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
    Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
    Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
    Carriere CH; Kang NH; Niles LP
    Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new Drosophila model to study the interaction between genetic and environmental factors in Parkinson's disease.
    Varga SJ; Qi C; Podolsky E; Lee D
    Brain Res; 2014 Oct; 1583():277-86. PubMed ID: 25130663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models.
    Xiong N; Long X; Xiong J; Jia M; Chen C; Huang J; Ghoorah D; Kong X; Lin Z; Wang T
    Crit Rev Toxicol; 2012 Aug; 42(7):613-32. PubMed ID: 22574684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Systemic Exposure to Low-Dose Rotenone Induced Central and Peripheral Neuropathology and Motor Deficits in Mice: Reproducible Animal Model of Parkinson's Disease.
    Miyazaki I; Isooka N; Imafuku F; Sun J; Kikuoka R; Furukawa C; Asanuma M
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.
    Caboni P; Sherer TB; Zhang N; Taylor G; Na HM; Greenamyre JT; Casida JE
    Chem Res Toxicol; 2004 Nov; 17(11):1540-8. PubMed ID: 15540952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.
    Normando EM; Davis BM; De Groef L; Nizari S; Turner LA; Ravindran N; Pahlitzsch M; Brenton J; Malaguarnera G; Guo L; Somavarapu S; Cordeiro MF
    Acta Neuropathol Commun; 2016 Aug; 4(1):86. PubMed ID: 27535749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.
    Schober A
    Cell Tissue Res; 2004 Oct; 318(1):215-24. PubMed ID: 15503155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial complex I inhibition depletes plasma testosterone in the rotenone model of Parkinson's disease.
    Alam M; Schmidt WJ
    Physiol Behav; 2004 Dec; 83(3):395-400. PubMed ID: 15581661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
    Takeuchi H; Yanagida T; Inden M; Takata K; Kitamura Y; Yamakawa K; Sawada H; Izumi Y; Yamamoto N; Kihara T; Uemura K; Inoue H; Taniguchi T; Akaike A; Takahashi R; Shimohama S
    J Neurosci Res; 2009 Feb; 87(2):576-85. PubMed ID: 18803299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic neurons are preferentially sensitive to long-term rotenone toxicity in primary cell culture.
    Radad K; Gille G; Rausch WD
    Toxicol In Vitro; 2008 Feb; 22(1):68-74. PubMed ID: 17923380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rotenone-induced rat model of Parkinson's disease: behavioral and electrophysiological findings.
    von Wrangel C; Schwabe K; John N; Krauss JK; Alam M
    Behav Brain Res; 2015 Feb; 279():52-61. PubMed ID: 25446762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of caloric vestibular stimulation in improvement of motor symptoms and inhibition of neuronal degeneration in rotenone model of Parkinson's disease - An experimental study.
    Thanalakshmi J; Archana R; Senthilkumar S; Shakila R; Pazhanivel N; Subhashini S
    Physiol Int; 2020 Oct; 107(3):390-405. PubMed ID: 33021954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal models of Parkinson's disease.
    Jackson-Lewis V; Blesa J; Przedborski S
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S183-5. PubMed ID: 22166429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
    Thakur P; Nehru B
    Neuroscience; 2013 Feb; 231():420-31. PubMed ID: 23159314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease.
    Concannon RM; Okine BN; Finn DP; Dowd E
    Exp Neurol; 2016 Sep; 283(Pt A):204-12. PubMed ID: 27317300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease.
    Pradhan S; Andreasson K
    Exp Neurol; 2013 Mar; 241():148-55. PubMed ID: 23261765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
    Testa CM; Sherer TB; Greenamyre JT
    Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.